MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15197693

Медицинская библиотека · Journal of clinical medicine · 2026

Clinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study.

Pinninti Rakesh, Subramaniyan Kiruthika, Iyer Rajagopalan, Rushdi Tasneem, Gulati Harveen Kaur, Akkineni Naga Prasanthi, Gupta Srinath, Mallavarapu Krishna Mohan, Nallacheruvu Yashaswini, Patnaik Sujit Chyau, Ayyagari Santa, Kodandapani Suseela, Koppula Veeraiah, Gudipudi Deleep, Thammineedi Subramanyeshwar Rao, Rajappa Senthil

СтатьяПеревод пока не подготовлен

Аннотация

Background

Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (OS).

Methods

We retrospectively reviewed 240 adults with histologically confirmed LMS diagnosed between January 2015 and May 2026. OS was calculated from diagnosis to death or last contact, with administrative censoring on 1 July 2026. Kaplan-Meier and Cox proportional-hazards methods were used to evaluate age, sex, anatomical site, histologic grade, and disease stage. Multivariable models adjusted for age, sex, grade, and stage assessed the independent association of anatomical site with OS.

Results

Median age was 56 years, and 152 patients (63.3%) were female. Disease was localized in 120 (50.0%), de novo metastatic in 53 (22.1%), recurrent metastatic in 35 (14.6%), and recurrent localized in 12 (5.0%). Median OS was 37.0 months. Localized disease was associated with substantially longer OS than metastatic disease (61.0 vs. 13.0 months; p < 0.001). Grade 3 disease was associated with shorter OS than grade 1/2 disease (25.6 vs. 61.1 months; p < 0.001). In multivariable analyses, metastatic disease remained strongly associated with inferior OS (HR, 5.59-5.94; p < 0.001), as did age ≥ 50 years (HR, 1.86-1.92; p = 0.006-0.004) and grade 3 histology (HR, 1.74-1.92; p = 0.018-0.007). Anatomical site was not independently associated with OS (extremity/trunk vs. non-extremity: HR, 1.60; p = 0.063; non-uterine vs. uterine: HR, 1.23; p = 0.41).

Conclusions

Disease stage was the strongest prognostic factor, while older age and grade 3 histology were independently associated with poorer OS. Although extremity/trunk LMS showed better univariable survival, anatomical site was not independently associated with OS after adjustment.

Для цитирования: Pinninti Rakesh, Subramaniyan Kiruthika, Iyer Rajagopalan, Rushdi Tasneem, Gulati Harveen Kaur, Akkineni Naga Prasanthi, Gupta Srinath, Mallavarapu Krishna Mohan, Nallacheruvu Yashaswini, Patnaik Sujit Chyau, Ayyagari Santa, Kodandapani Suseela, Koppula Veeraiah, Gudipudi Deleep, Thammineedi Subramanyeshwar Rao, Rajappa Senthil. Clinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15197693.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.